Homocysteine and cardiovascular disease

被引:70
作者
Kalra D.K. [1 ]
机构
[1] Heart Associates, Houston, TX 77030
关键词
Folate; Homocysteine; Fenofibrate; Homocysteine Level; Hyperhomocysteinemia;
D O I
10.1007/s11883-004-0097-3
中图分类号
学科分类号
摘要
Research over the past decade has shown that elevated levels of homocysteine have a strong association with all forms of atherothrombotic disease and venous thromboembolism. This association is particularly strong for coronary disease and newer data indicate that screening for homocysteine levels may be warranted in those with unexplained thrombotic tendencies and in young patient who develop coronary event or disease without the usual predisposing factors such as hypertension, smoking, hypercholesterolemia, or diabetes. Although the link between hyperhomocysteinemia and cardiac disease has not been conclusively shown to be causal as yet, data are emerging that lowering homocysteine levels may be beneficial in patients as high risk. Such lowering can be done safely and inexpensively with increased intake of fruits and vegetables and in those patients who are particularly at high risk using supplementation with folic acid and the B vitamins. Preliminary studies have shown that lowering homocysteine levels in this manner may slow the progression of atherosclerosis in coronary and carotid vessels. No mortality data exit yet showing that reducing homocysteine reduces cardiac or total mortality, although it is likely that ongoing and planned trials that are underway will shed light on these important questions soon. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:101 / 106
页数:5
相关论文
共 21 条
[1]  
Malinow M.R., Boston A.G., Krauss R.M., Homocyst(e)ine, diet, and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee, American Heart Association, Circulation, 99, pp. 178-182, (1999)
[2]  
Wald D.S., Law M., Morris J.K., Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis, BMJ, 325, (2002)
[3]  
Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G., A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes, JAMA, 274, pp. 1049-1057, (1995)
[4]  
Nygard O., Nordrehaug J.E., Refsum H., Et al., Plasma homocysteine levels and mortality in patients with coronary artery disease, N. Engl. J. Med., 337, pp. 230-236, (1997)
[5]  
Anderson J.L., Muhlestein J.B., Horne B.D., Et al., Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease, Circulation, 102, pp. 1227-1232, (2000)
[6]  
Hoogeveen E.K., Kostense P.J., Eysink P.E., Et al., Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: The Hoorn study, Arch. Intern. Med., 160, pp. 2984-2990, (2000)
[7]  
Stubbs P.J., Al Obaidi M.K., Conroy R.M., Et al., Effect of plasma homocysteine concentration on early and late events in patients wit acute coronary syndromes, Circulation, 102, pp. 605-610, (2000)
[8]  
Schnyder G., Roffi M., Pin R., Et al., Decreased rate of coronary restenosis after lowering of plasma homocysteine levels, N. Engl. J. Med., 345, pp. 1593-1600, (2001)
[9]  
Graham I.M., Daly L.E., Refsum H.M., Et al., Plasma homocysteine as a risk factor for vascular disease, JAMA, 277, pp. 1775-1781, (1997)
[10]  
Nishio E., Watanabe Y., Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: A possible role for hydrogen peroxide, Br. J. Pharmacol., 122, pp. 269-274, (1997)